CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
E6011 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02960490
NCT02960490Phase 2Completed
CompareCT.gov

A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics

Eisai Co., Ltd.·interventional·Posted Nov 9, 2016·Updated Aug 23, 2021

In Brief

A Phase 2 clinical trial evaluating E6011 and Placebo for Rheumatoid Arthritis. Completed, enrolled 66 participants across 45 sites.

Detailed Summary

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study in rheumatoid arthritis participants inadequately responding to biologics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 9, 2016
Enrollment StartNov 26, 2016
Primary CompletionMay 16, 2018
Study CompletionNov 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.6 years ago

Interventions

E6011drug

subcutaneous administration

Placebodrug

subcutaneous administration